AUROPHARMA - Swing Trade Analysis with AI Signals
← Back to ListKey Parameters
⭐ Swing Trade Rating: 3.7
✅ Positive
Aurobindo Pharma has shown strong earnings growth over the past two quarters, increasing from 595 Cr to 692 Cr PAT. The company’s debt-to-equity ratio of 0.19 indicates a conservative financial structure and healthy liquidity.
⚠️ Limitation
Despite robust revenue growth, the stock trades at a high P/E ratio of 37.2, reflecting investor optimism but also potential downside risk if earnings don't maintain this trajectory. The PEG ratio of 1.44 suggests the stock is overvalued relative to its growth rate.
📉 Company Negative News
Recent news indicates an upcoming AGM and a licensing pact with Merck, which are standard corporate events and do not inherently represent negative information.
📈 Company Positive News
None found
🏭 Industry
The pharmaceutical sector is generally considered stable and growing, driven by increasing healthcare demand globally. Aurobindo Pharma operates within the generic drug segment, benefiting from patent expirations and opportunities for cost-effective medication supply.
🧾 Conclusion
A potential entry point could be around 1,520 ₹, utilizing a breakout strategy following a short-term upward movement. To exit, consider setting a stop-loss order at 1,480 ₹ if the stock declines sharply, or target a profit of 1,600 ₹ based on anticipated upside potential given the recent earnings growth. Overall, this stock presents a moderate swing trading opportunity with typical risk/reward considerations.